業聚醫療(06929.HK)2024年度營收穩增至1.64億美元 亞太地區市場收入同比大增43.7%
格隆匯3月7日丨業聚醫療(06929.HK)公佈年度業績，截至2024年12月31日止年度，集團收入爲1.64億美元，同比增長6.6%，此乃得益於美國市場的銷售回升及亞太地區市場的持續增長。撇除匯兌影響，收入同比增幅爲8.7%。於2024年，銷量達1.7百萬件，其中1.5百萬件爲自有產品，同比增加4.8%。毛利增加7.5%至約1.14億美元，公司擁有人應佔年內利潤達3971.7萬美元。
亞太地區是集團2024年收入增長的主要動力。來自亞太地區市場的收入達5220萬美元，同比大幅增長43.7%。此驕人表現歸因於新收購的印尼及韓國分銷商所帶來合共達1150萬美元的外部增長，以及馬來西亞、新加坡、香港、越南及印度等市場所帶來的強勁內部同比增長達13.8%。其中，最新一代刻痕球囊Scoreflex TRIO自2024年初在馬來西亞推出後銷量迅速攀升。
來自歐洲、中東及非洲的收入同比穩步增長7.9%，達到3920萬美元。該增長乃主要由於集團的自有球囊產品在直銷市場(如德國及西班牙)以及分銷市場(如捷克共和國、斯洛伐克及英國)的銷量有所增加。然而，於雅培收購CSI後，因集團與CSI有關旋磨產品(第三方產品)的分銷協議終止，抵銷了部分收入升幅。
2024年集團繼續藉覆蓋全球逾70個國家和地區的廣泛銷售網絡銷售產品。具體而言，集團已於12個國家及地區設立直銷團隊，包括中國境內、香港、澳門、法國、德國、摩納哥、印尼、日本、馬來西亞、新加坡、西班牙及瑞士。截至2024年12月31日，集團共有266名銷售和營銷人員(截至2023年12月31日：221名)及207家分銷商(截至2023年12月31日：234家)。年內，直銷及分銷商銷售分別貢獻約94.8百萬美元及69.3百萬美元收入，佔集團總收入57.7%及42.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
